MedImmune and Abpro announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). The agreement is structured as a spin out, benefiting from both companies’ scientific expertise and AbPro’s day-to-day leadership as it oversees the new company, AbMed.
Several potential therapeutic areas will be explored where inhibition of the Ang2 and VEGF pathways with this unique bispecific antibody may provide clinical benefit.
Scientists at MedImmune leveraged the company’s significant experience with bispecific antibody development, engineering a novel bispecific antibody that demonstrated potent activity in animal models, which may be useful in targeting disease indications with high unmet need. AbPro will bring strong scientific, technical and clinical expertise to the new company moving forward, and its core technology platform, DiversImmune, will be used to further refine the antibody.
“This agreement arises out of MedImmune’s culture of entrepreneurship and innovation — both in science and in business,” said Jane Osbourn, Vice President of R&D, MedImmune. “We believe partners like Abpro can help us maximize our extensive pre-clinical portfolio to advance therapies for patients.”
Ian Chan, CEO and Co-founder of Abpro said: “This collaboration further validates our platform’s ability to develop therapeutic antibodies against traditionally difficult targets, with compelling prospects for potential clinical utility.”
Story from MedImmune. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.